The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
Subscribe To Our Newsletter & Stay Updated
